Vaxcyte, Inc. $PCVX Shares Sold by China Universal Asset Management Co. Ltd.

China Universal Asset Management Co. Ltd. lessened its holdings in shares of Vaxcyte, Inc. (NASDAQ:PCVX) by 28.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 22,756 shares of the company’s stock after selling 9,154 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Vaxcyte were worth $820,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. CWM LLC increased its position in Vaxcyte by 197.3% in the 2nd quarter. CWM LLC now owns 1,680 shares of the company’s stock valued at $55,000 after acquiring an additional 1,115 shares during the period. Virtus Investment Advisers LLC increased its holdings in shares of Vaxcyte by 45.8% during the second quarter. Virtus Investment Advisers LLC now owns 2,729 shares of the company’s stock valued at $89,000 after purchasing an additional 857 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Vaxcyte by 96.3% during the third quarter. Nisa Investment Advisors LLC now owns 3,254 shares of the company’s stock valued at $117,000 after purchasing an additional 1,596 shares in the last quarter. Osaic Holdings Inc. raised its stake in shares of Vaxcyte by 110.8% during the second quarter. Osaic Holdings Inc. now owns 3,859 shares of the company’s stock valued at $128,000 after purchasing an additional 2,028 shares in the last quarter. Finally, AlphaQuest LLC lifted its holdings in Vaxcyte by 401.6% in the second quarter. AlphaQuest LLC now owns 4,429 shares of the company’s stock worth $144,000 after purchasing an additional 3,546 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Price Performance

PCVX stock opened at $58.51 on Friday. The firm has a market cap of $7.66 billion, a PE ratio of -12.09 and a beta of 1.33. Vaxcyte, Inc. has a 12 month low of $27.66 and a 12 month high of $84.01. The firm has a 50 day simple moving average of $50.05 and a 200 day simple moving average of $42.88.

Insider Buying and Selling at Vaxcyte

In related news, SVP Elvia Cowan sold 11,623 shares of Vaxcyte stock in a transaction on Tuesday, December 23rd. The stock was sold at an average price of $47.92, for a total value of $556,974.16. Following the transaction, the senior vice president directly owned 14,534 shares in the company, valued at $696,469.28. The trade was a 44.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Harpreet S. Dhaliwal sold 9,743 shares of the business’s stock in a transaction on Wednesday, December 31st. The stock was sold at an average price of $46.69, for a total value of $454,900.67. Following the sale, the insider directly owned 23,928 shares in the company, valued at $1,117,198.32. This trade represents a 28.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.10% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on PCVX shares. Guggenheim reissued a “buy” rating and set a $116.00 target price on shares of Vaxcyte in a research note on Monday, February 2nd. BTIG Research reiterated a “buy” rating and issued a $85.00 price objective on shares of Vaxcyte in a report on Monday, November 10th. Needham & Company LLC boosted their target price on Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, January 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Vaxcyte in a research report on Friday, January 9th. Finally, Leerink Partners set a $77.00 price target on Vaxcyte and gave the company an “outperform” rating in a research report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Vaxcyte has an average rating of “Moderate Buy” and a consensus target price of $93.83.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.